(0.34%) 5 117.22 points
(0.27%) 38 344 points
(0.33%) 15 981 points
(-0.72%) $83.25
(2.44%) $1.970
(-0.02%) $2 346.70
(-0.10%) $27.51
(3.03%) $950.05
(-0.09%) $0.934
(-0.12%) $11.01
(-0.32%) $0.798
(1.51%) $93.26
@ $11.35
Išleistas: 14 vas. 2024 @ 16:30
Grąža: -0.70%
Ankstesnis signalas: vas. 13 - 16:30
Ankstesnis signalas:
Grąža: 3.37 %
Live Chart Being Loaded With Signals
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers...
Stats | |
---|---|
Šios dienos apimtis | 21 230.00 |
Vidutinė apimtis | 829 708 |
Rinkos kapitalizacija | 799.72M |
EPS | $0 ( 2024-03-06 ) |
Kita pelno data | ( $-0.850 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.52 |
ATR14 | $0.0460 (0.41%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Vultaggio Vincent | Sell | 0 | Common Stock |
2024-04-05 | Vultaggio Vincent | Sell | 12 500 | Stock Option (Right to Buy) |
2024-04-05 | Vultaggio Vincent | Sell | 10 000 | Stock Option (Right to Buy) |
2024-04-05 | Vultaggio Vincent | Sell | 6 875 | Stock Option (Right to Buy) |
2024-04-05 | Vultaggio Vincent | Sell | 2 750 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
85.13 |
Last 97 transactions |
Buy: 9 826 125 | Sell: 711 798 |
Tūris Koreliacija
Zentalis Pharmaceuticals Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
RAVN | -0.813 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Zentalis Pharmaceuticals Koreliacija - Valiuta/Žaliavos
Zentalis Pharmaceuticals Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-1.39M (0.00 %) |
EPS: | $-4.47 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-1.39M (0.00 %) |
EPS: | $-4.47 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $-1.43M (0.00 %) |
EPS: | $-4.18 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-5.65 |
Financial Reports:
No articles found.
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.